THE ECONOMIC RATIONALE FOR THE SUPPLEMENTATION OF CHOLECALCIFEROL IN THE TREATMENT OF HYPERTENSION

The aim of the study was to calculate the costs of lowering blood pressure (BP) in complex antihypertensive therapy of arterial hypertension (AH) with and without cholecalciferol. Material and methods. A total of 154 patients with grade II AH were included into the study. They were divided into the AH(+)Х group - those who received combined antihypertensive therapy plus cholecalciferol 2000 IU / day and the comparison group - AH(-)Х. Office BP and total vitamin D levels were measured. The costs of drug therapy were calculated. Results. On repeated examination, the level of vitamin D in the blood increased and in the AH(+)Х group it became higher (p = 0.0000001) than in the AH (-)Х group. The cost of drug therapy per person in the AH(+)Х group was higher than in the AH(-)Х group ($ 106.8 and $ 91.5, respectively), but the cost of reducing 1 mm Hg systolic BP in the AH(+)Х group was $ 3.9 less than in the AH(-)Х group.Conclusion. The economic costs of reducing systolic BP, with more frequent achievement of its target values, were the lowest in the complex therapy with cholecalciferol, especially in combination with a diuretic.